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INTRODUCTION
Ischemia and reperfusion (I/R) is a pathological condition 
characterized by an initial shortage of blood flow to an or-
gan followed by the subsequent restoration of perfusion and 
concurrent re-oxygenation. Occlusion of the arterial blood 
flow, such as that happens as a result of an embolus, caus-
es tissue hypoxia with subsequent metabolic and patholog-
ical changes. Surprisingly, restoration of blood supply and 
reoxygenation is commonly associated with activation of 
several pathways that lead to exacerbation of inflammatory 
response and profound tissue damage (called ‘reperfusion 
injury’) [1]. I/R injury is responsible for pathological events 
in a wide range of conditions; the most extensively studied 
of which is cardiac arrhythmia and arrest associated with 
myocardial ischemia and infarction [2]. Other forms of tis-
sue injury are associated with ischemia of multiple organs 
and subsequent reperfusion injury when blood flow is re-
stored. Moreover, the untoward effects of I/R are not only 
restricted to the specific tissue/organ undergoing the initial 
ischemia but also extend to include injury to other organs 
distant to the ischemic tissue as a result of mediator release 
into the bloodstream draining the revascularized tissues and 
subsequent transport to remote organs, so-called distant or 
remote organ injury. This phenomenon was studied in most 
tissues including gut [3], lung [4], liver [5], kidney [6], skel-
etal muscle [7], and heart [8].
The liver is an example the organs that is frequent-
ly exposed to I/R injury during variety of conditions such 
as tumor resection surgery and liver transplantation. Liver 
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transplantation is the standard of care in patients with end-
stage liver disease (ESLD) and those with tumors of hepatic 
origin [9]. In Egypt, hepatitis C virus (HCV), and its long-
term complications, is a major endemic health problem 
leading to ESLD. An Egyptian demographic health survey 
conducted in 2008 concluded that 14.7% of the population 
have been infected, making this the highest prevalence in 
the world [10], with much higher rates at around 26% and 
28% in the Nile Delta and Upper Egypt respectively [11-12]. 
The vast majority of these patients eventually require liver 
transplantation. In our University of Mansoura, Egypt, the 
Gastrointestinal Surgery Center is leader in liver transplan-
tation surgery. On Wednesday 1st March 2017, a ceremony 
was organized by Mansoura University to celebrate Case No. 
500 for liver transplantation program. Adding that two cases 
are currently being transplanted weekly and there are more 
than 200 cases on waiting lists, and that the university seeks 
life for every patient [13].
Organ shortage has prompted the ultimate care of do-
nors’ livers during the transplantation surgery through 
avoiding prolonged periods of ischemia. However, liver isch-
emia is unavoidable issue during transplantation surgery 
making the organ particularly susceptible to I/R injury as a 
result of cellular damage during procurement, preservation 
and surgery. Undoubtedly, I/R injury might lead to poor 
early graft function and primary nonfunction, and further-
more, to both acute and chronic graft rejection. So, effective 
therapeutic strategies are mandatory to prevent acute com-
plications resulting from I/R injury during hepatic resection 
and transplantation, and to improve the survival of usable 
donor grafts.
Development of effective therapeutic strategies to pre-
vent hepatic I/R injury depends on our understanding of 
the mechanisms and pathogenesis of I/R injury which, un-
fortunately, remains not well-understood. Several factors/
downstream signaling pathways have been implicated in the 
hepatic I/R injury process, including oxidative stress, anaer-
obic metabolism, mitochondria, intracellular calcium over-
load, liver Kupffer cells (KC) and neutrophils, and cytokines 
and chemokines [14].
The overall aim of this review, however, is to provide in-
sights into the mechanisms of liver I/R injury, indicating the 
potential role of oxidative stress, inflammatory cytokines, 
and the role of nuclear factor kappa beta (NF-κB) in the 
pathogenesis of liver I/R injury, and the protective factors/
pathways that may help to improve therapeutic regimens 
for controlling hepatic I/R injury during liver transplanta-
tion surgery. We take into consideration the major role of 
calcium ions and the renin-angiotensin system (RAS) in the 
process of I/R injury.
Types and stages of liver I/R injury
Ikeda and co-workers had previously described two major 
types of liver injury that are attributable to ischaemia–reper-
fusion in the rat model, the ‘warm’ and the ‘cold’ types [15]. 
The ‘warm’ I/R injury, with the hepatocellular damage as the 
prominent feature, develops in situ during liver transplan-
tation surgery or during various forms of shock or trauma, 
and might lead to liver or even multiorgan failure. The ‘cold’ 
I/R injury, with damage to hepatic sinusoidal endothelial 
cells (SEC) and disruption of the microcirculation as the 
prominent features, occurs during ex vivo preservation and 
is usually coupled with warm I/R injury during liver trans-
plantation surgery. 
Although initial cellular targets of the two I/R injury types 
might be different, they do share a common mechanism in 
the disease etiology; that is, local inflammatory innate im-
mune activation. The activation of liver KC and neutrophils, 
the production of cytokines and chemokines, the generation 
of reactive oxygen species (ROS), increased expression of 
adhesion molecules and infiltration by circulating lympho-
cytes and/or monocytes are immunological cascades present 
in both types of I/R injury [16]. Schematic representation of 
these stages is presented in Fig 1.
Most studies elucidated the mechanistic insights into the 
stages of liver I/R injury had been conducted on transgenic 
knockout models and in an in situ model of segmental he-
patic warm I/R in mice [14, 17]. A clinically more relevant 
mouse model, combining cold and warm I/R injury compo-
nents followed by liver transplantation, has only been estab-
lished by Shen and co-workers in 2005 [18]. These studies 
have distinguished two distinct stages of liver I/R injury, 
with unique mechanisms of hepatic damage. The initial in-
sult is an ischemic injury results from glycogen consump-
tion, lack of oxygen supply which lead to mitochondrial 
dysfunction and ultimately to ATP depletion and hepatocyte 
cell death. The second is a reperfusion injury, which follows 
the ischemic injury and results primarily from an intense in-
flammatory immune response that includes both direct and 
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indirect cytotoxic mechanisms. This inflammatory immune 
response activated by I/R promptly converts the immuno-
logically quiescent liver into an inflammatory organ; even in 
a sterile environment [1, 17, 18]. This inflammatory immune 
response is critical in hepatic I/R injury as prevention of lo-
cal immune activation have been shown to ameliorate I/R 
injury [19]. Therefore, good understanding the scenario of 
immune activation is important for discovering novel ther-
apeutic targets that would be able to block the proinflam-
matory mechanisms whilst sparing the anti-inflammatory 
mechanisms. 
Types of cell injury and death
There is evidence that hepatocytes and SEC are the two main 
cell types that are directly injured in both cold and warm 
I/R injury. Hepatocytes are more sensitive to warm ischemic 
injury (37 °C), while SEC are more sensitive to cold ischemia 
(4 °C) that occur in cold preservation of donor liver grafts 
before transplantation. Exclusive pathological injury of sin-
gle cell type is not known [17].
Although the causes of cell death are variable, the mode 
of hepatic cell death typically follows one of two patterns. 
The first leads to a pathologic pattern of necrosis, the pro-
cess of which is called “oncosis” or “oncotic necrosis”. Oncot-
ic necrosis is typically the consequence of acute metabolic 
distress resulting from IR. Apoptosis, in contrast, represents 
the implementation of a death program often initiated by 
quite specific stimuli [20]. Apoptosis leads to the systematic 
resorption of individual cells that minimizes inflammatory 
responses and leakage of cellular components into the extra-
cellular space. Apoptosis and necrosis are usually considered 
separate issues, but an alternate view is emerging that apop-
Fig 1. The distinct stages of liver ischemia–reperfusion injury. Ischemic injury, a localized process of hepatic metabolic disturbances, results from 
glycogen consumption, lack of oxygen supply and ATP depletion. The cell death, activation of complement and mitochondrial reactive oxygen 
species (ROS) production all contribute to liver immune activation after reperfusion, which involves multiple liver cell types, including Kupffer cells 
(KC), natural killer (NK) T cells, and polymorphonuclear cells (PMNs). The ischemia–reperfusion-activated proinflammatory immune cascade 
sustains itself by recruiting peripheral immune cells from the circulation, and is responsible for the ultimate liver reperfusion injury [Reproduced 
from Zhai et al., 2012].
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tosis and necrosis are frequently the consequence of the same 
initiating factors and signaling pathways. Rather than being 
separate entities, apoptosis and necrosis in their pure form 
may represent extremes on a continuum of cell death [21]. 
However, the relative contribution of necrotic and apoptotic 
cell death to the overall liver injury during hepatic I/R is still 
controversial. Apoptosis is an energy dependent process, so 
theoretically when there is excessive depletion of ATP, ne-
crosis should predominate. Also, necrosis takes longer time 
to become evident, normally more than 3 h. This is challeng-
ing to demonstrate experimentally in vivo, as tissue ATP be-
fore and after reperfusion would need to be measured as well 
as the altered metabolic activity of the cell. Many of the same 
factors and pathways are involved in both types of cell death, 
so there is much overlap. A new term “necrapoptosis” [22] 
or “necroptosis” [23] has been coined to describe a process 
that begins with a common death signal and culminates in 
either cell lysis (necrotic cell death) or programmed cellular 
resorption (apoptosis), depending on factors such as the de-
cline of cellular ATP levels.
A common event leading to both apoptosis and necrosis 
is mitochondrial permeability transition (MPT) pore forma-
tion (discussed below) and dysfunction, although the mech-
anistic basis of mitochondrial injury may vary in different 
settings. Prevention of these modes of cell death is an im-
portant target of therapy, but controversies still exist regard-
ing which mode of cell death predominates in various forms 
of liver disease and injury. Resolution of these controversies 
may come with the recognition that apoptosis and necrosis 
frequently represent alternate outcomes of the same cellular 
pathways to cell death, especially for cell death mediated by 
mitochondrial MPT pore. An understanding of processes 
leading to liver cell death will be important for development 
of effective treatments to prevent hepatocellular death fol-
lowing hepatotoxins or I/R injury and prevent liver cell fail-
ure due to various pathologies [23]. 
Different assay methods have been utilized to identify 
and quantify apoptosis, including assay for various proapop-
totic proteins such as caspase-3 which is thought to be a spe-
cific indicator of apoptosis, and Bax. The Terminal Deoxy-
nucleotidal Transferase dUTP Nick End Labeling (TUNEL) 
procedure is a very common method for examining DNA 
fragmentation that results from apoptosis. Although TUNEL 
is a very effective technique for apoptosis assay, one major 
limitation of this approach is that TUNEL detects apoptotic 
cells at the latest stage in the process. Varying levels of apop-
tosis and necrosis have been described in the literature for 
different ischemia reperfusion models, but these conclusions 
on the different degrees of apoptosis versus necrosis need to 
be interpreted carefully as most assay methods for apoptosis 
are relatively nonspecific [24].
Mechanisms underlying liver I/R injury
The mechanisms of liver I/R injury have been extensive-
ly studied, but nevertheless remain generally unclear [25]. 
Fig 2. Necrosis and apoptosis as alternate outcomes of mitochondrial 
permeabilization. Ischemia/reperfusion, hepatotoxins and 
other stresses converge on mitochondria to induce membrane 
permeabilization. Permeabilization may involve formation of channels 
in the outer membrane or induction of a cyclosporin (CsA) sensitive 
MPT followed by mitochondrial swelling and outer membrane 
rupture. Other stresses act directly to cause the MPT. After membrane 
permeabilization, cytochrome c is released to the cytosol and activates 
in sequence caspase 9 and caspase 3 in a reaction requiring Apaf1 
and ATP. With severe and pervasive mitochondrial dysfunction, ATP 
decreases in part due to activation of the mitochondrial uncoupler-
stimulated ATPase. With ATP depletion, caspase activation is blocked, 
and necrosis occurs instead [From Malhi et al., 2006].
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The factors/pathways implicated in the hepatic I/R injury 
process include anaerobic metabolism and acidosis, mito-
chondrial damage, oxidative stress, disrupted intracellular 
calcium overload, liver KC and neutrophils, and cytokines 
and chemokines. More importantly, an effective prevention 
or treatment method remains unavailable. 
Anaerobic metabolism
Liver I/R injury exerts broad spectrum metabolic effects on 
the body. Immediately after arterial blood has been cut off 
the liver, the metabolic pattern is shifted from aerobic to an-
aerobic leading to stopping of mitochondrial oxidative phos-
phorylation of the hepatocytes and accumulation of acidic 
metabolites, such as H+ ions, lactic acid and ketone bodies 
[25]. When mitochondrial ATP is considerably depleted, all 
intracellular ATP-dependent metabolic and enzymatic func-
tions are gradually ceased off. However, after the pH restore 
to normal values with reperfusion, activation of intracellu-
lar pH-dependent proteases and phospholipases takes place 
leading to more worsening of tissue damage. This is called 
the pH paradox [17]. The toxicity resulting from acidic envi-
ronment and low ATP results also in disturbance of Na+ and 
calcium homeostasis, impairment of the cellular functions, 
signaling interactions, and sodium/potassium ATPase (Na+/
K+-ATPase), leading finally to mitochondrial damage and 
cell death [26].
Mitochondrial dysfunction
The mitochondria are the place where oxidative phosphory-
lation mainly takes place. Many studies have shown that mi-
tochondrial dysfunction plays a critical role in the process of 
hepatocyte damage after I/R injury [27, 28, 29]. Opening of a 
non-specific pore in the mitochondrial inner membrane that 
is called the mitochondrial permeability transition (MPT) 
pore is a critical event in the progression of cell death in re-
sponse to I/R injury (also known as mitochondrial permeal-
ization). During the ischemic period, the inner MPT pore is 
kept quiescent being inhibited by the low pH. However, upon 
reperfusion, the huge increases in mitochondrial Calcium, 
coupled with excess formation of ROS, induce opening of 
the MPT pore [27]. The pore can pass any molecule < 1500 
Dalton, and therefore, H+ ions can pass back into the matrix 
through this channel, thereby inhibiting electron transport 
and ATP synthesis [30]. In addition, water molecules enter 
the mitochondria under osmotic gradient causing the mito-
chondria to swell and even rupture which leads eventually 
to hepatocyte cell death. The extent to which pores remain 
open correlates directly with the duration of ischemia and 
inversely with the recovery of cells. Agents or protocols 
that protect against MPT pore opening such as cyclosporin 
A [31], melatonin [32] and edaravone [33] were shown to 
provide mitochondrial protection against reperfusion inju-
ry. In a recent review, Bernardia and Di Lisa have recently 
discussed the molecular mechanism of the mitochondrial 
permealization and its significance in cell response to ROS 
and ischemic injury [34]. 
Oxidative stress
A substantial body of literature has shown that oxidative 
stress plays a crucial role in I/R injury [35-37]. Many highly 
reactive ROS molecules including superoxide anions, hy-
droxyl radicals, and peroxide hydrogen are generated during 
the period of hepatic I/R injury. These reactive molecules 
attack many cellular organelles, proteins, lipids, and nucleic 
acids leading to enzyme inhibition, mitochondrial instability 
and formation of deleterious lipid peroxides. ROS can also 
damage endothelial cells and destroy the integrity of the mi-
crocirculatory system. There are thought to be three main 
pathways for the generation of ROS: conversion of xanthine 
dehydrogenase to xanthine oxidase (XO) during ischemia, 
activation of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, and uncoupling of the mitochondrial 
electron transport chain. Although hepatocytes can direct-
ly generate ROS, physiologically KC are thought to be the 
main source of ROS in the early stages of liver I/R injury 
with natural killer T-cells being the main source later, and 
neutrophils being the main source in the very later stages 
[38-39]. Many studies have shown that antioxidants, such as 
superoxide dismutase, catalase, glutathione, α-tocopherol, 
or herbal antioxidants exerted some protection against I/R 
injury induced by ROS [35-36]. On the other hand, recent 
researches have investigated the role of nuclear transcrip-
tion factors controlling the function and expression of genes 
coding for natural antioxidant defense components in com-
bating ischemia–reperfusion-induced oxidant stress [40]. 
Individual oxidation stress-related gene armamentarium has 
been also studied in hepatic I/R injury models [41].
Microcirculatory dysfunction
Microcirculatory disturbance plays an important part in 
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hepatic I/R injury. Reduction in sinusoidal caliper and di-
minished blood flow are among the earliest changes in 
reperfusion injury. This results from a combination of di-
rect damage to liver SEC, together with vasoconstriction 
and expression of adhesion molecules with accumulation of 
platelets and leucocytes. Two of the key vasoactive players 
that maintain sinusoidal vascular tone are the vasoconstric-
tor endothelin-1 (ET-1), and the vasodilator and inhibitor of 
platelet aggregation, nitric oxide (NO). In the early stages of 
liver I/R injury, there is a relative excess of ET-1 [17].
Liver transplantation in pigs has provided evidence that 
after reperfusion KC activation leads to increased release of 
ET-1 which binds to endothelin-A receptors on SEC and 
hepatocyte, thereby reducing hepatic micro and macro-cir-
culation resulting in accelerated liver injury. The activation 
of this pathway is associated with increased expression of 
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and 
endothelial nitric oxide synthase (eNOS) [42]. Some stud-
ies have shown that carbon monoxide and NO, which are all 
vasodilators, are likely play a role in reducing the severity of 
liver I/R injury [25, 43].
Cytosolic calcium overload
Physiologic intracellular calcium concentration is about 
10–100 nM, which is 10,000 folds less than the extracellu-
lar concentration. This gradient is essentially maintained 
by four mechanisms: (1) the ATP-dependent transmem-
brane efflux pump; (2) the Na+/K+ mediated Na+/calci-
um exchange pump; (3) the ATP-dependent calcium stores 
present in the endoplasmic reticulum; and (4) the mito-
chondrial oxygen-dependent calcium pump [44]. Under 
ischemic conditions, the absence of oxygen stops oxidative 
phosphorylation and diminishes ATP, thereby, the energy 
source by which three of the four mentioned mechanisms 
that preserve hepatocellular calcium homeostasis is deplet-
ed. This, in turn, leaves nonselective cell membrane calcium 
entry channels unopposed, resulting in increase in calcium 
entry [45]. Mitochondrial sequestration, the last of the four 
mechanisms, subsequently overloads the mitochondria with 
calcium causing more inhibition of oxidative phosphoryla-
tion as oxygen levels are further depleted [46]. In addition, 
and as a consequence of ischemia, the cytosolic pH falls due 
to accelerated anaerobic glycolysis. In an attempt to reestab-
lish normal pH, hepatic cells extrude H+ ions in exchange 
for Na+ via a NHE. The Na+ ions are then exchanged for 
calcium by another Na+/Calcium exchanger causing a net 
increase in cytosolic calcium [47]. Furthermore, endoge-
nous release of cytosolic calcium stored in the endoplasmic 
reticulum is also enhanced through activation of ryanodine 
receptors [48]. Upon reperfusion, there is neutrophil accu-
mulation and release of ROS and inflammatory cytokines 
by the activated neutrophils and KC which further devastate 
the cellular damage and capillary degradation. Prior to the 
reestablishment of oxygen, the hydrolysis of ATP is believed 
to accumulate hypoxanthine, a precursor of free-radical for-
mation. In addition, the increased intracellular calcium from 
the ischemic phase promotes the production of conversion 
of xanthine dehydrogenase into XO, a proteolytic enzyme 
involved in free-radical synthesis. Thus, during reperfusion 
the re-oxygenation of cells causes (1) XO-induced produc-
tion of ROS; and (2) restoration of ATP levels, which, in 
turn, allows active uptake of calcium by the mitochondria, 
resulting in massive calcium overload and destruction of the 
mitochondria. 
Normally the level of calcium inside the mitochondria 
is low, but as cytoplasmic calcium increases, the mitochon-
dria can act as a buffering box for the excess calcium [48]. 
During overload, however, the mitochondrial Na+/Calcium 
exchanger is overwhelmed, allowing mitochondrial levels to 
become high enough to trigger activation of the MPT pore 
in the inner mitochondrial membrane with subsequent cell 
death by apoptosis or necrosis [27]. The rise of cytosolic cal-
cium associated with I/R injury can also induce patholog-
ical activation of Calcium/CaM-dependent protein kinase 
II, PKA, and PKC [23] and activate calcium dependent cal-
pain family of proteases that can degrade a number of intra-
cellular proteins [49]; all of these events join forces to cell 
death and organ dysfunction. Studies have also shown that 
a period of I/R alters the redistribution of calcium between 
cellular and subcellular compartments leading to release of 
unwanted autophagosomes, plasma membrane crumbling, 
mitochondrial dysfunction, and nuclear condensation [50].
Calcium channel blockers (CCBs) include phenylalkyl-
amines (e.g. verapamil), dihydropyridines (e.g. nifedipine, 
amlodipine, and nimodipine), and benzothiazepines (e.g. 
diltiazem). calcium channel blockers of dihydropyridine 
group, such as nimodipine, are derived from the molecule 
dihydropyridine and often used to reduce systemic vascular 
resistance and arterial pressure, and to prevent cerebral va-
sospasm [51]. 
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Several reports have suggested that different CCBs im-
prove survival in hepatic I/R injury owing to their ability 
to inhibit the increase of cytosolic calcium in hepatocytes 
during I/R and prevent mitochondrial toxicity [52-53]. In 
one study supporting this assumption, amlodipine prevent-
ed hepatocyte cellular damage and preserved mitochondrial 
integrity by inhibiting the calcium channels of hepatocytes 
in rat liver I/R injury [53]. Other reports, however, suggest 
that the protective role of CCBs is not only due to preventing 
an increase in hepatic calcium concentration in parenchy-
mal cells, but also seem to protect the liver from ischemic 
injury by acting on sinusoidal lining or vascular cells rather 
than on parenchymal cells [54]. 
Hepatic tissue blood flow has been considered to play an 
important role in hepatic I/R events, and in liver transplanta-
tion, graft microcirculation failure is considered a major de-
terminant of postischemic liver injury [16]. A previous study 
reported that amlodipine attenuated hepatic I/R injury by 
cytoprotective effects on parenchymal and non-parenchy-
mal hepatocytes during both preservation and reperfusion 
Fig 3. Overview of calcium-mediated intracellular signaling pathways. Calcium initially enters the cell through transmembranous channels and 
receptors prior to pooling the cytoplasm where free calcium resides. The plasma membrane calcium-entry pathways include calcium store-operated 
channels, receptor-activated channels, and ligand-gated channels. Calcium outflow across the plasma membrane is controlled by Ca2+/Mg2+ 
ATPase and Na+/Ca2+ exchanger. Located in the cytoplasm, calcium-dependent proteins, such as PKA, PKC, calpain, and calmodulin (collectively 
represented by triangular P). Mitochondrial calcium uptake is mediated by its uniporters, whereas outflow is managed by MPT pore and Na+/Ca2+ 
and Ca2+/H+ antiporters. Calcium is released from endoplasmic reticulum by IP3R and RyR. Nuclear transcription factors such as NF-κB are 
upregulated by cytoplasmic proteins [Reproduced from Chang et al., 2010].
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by improvement of microvascular circulation and inhibition 
of mediator release [55]. Chin and co-workers have also re-
ported that the protective effect of the calcium antagonist 
diltiazem in liver I/R injury was mainly due to improvement 
in microvascular circulation [56]. Other calcium channel an-
tagonist verapamil was demonstrated to have a modest pro-
tective effect in hepatic I/R injury mainly by prevention early 
generation of ROS [57]. 
On the other hand, systemic hypertension is a common 
complication after liver transplantation. Several studies have 
reported that about 50% or more of the liver transplant re-
cipients develop hypertension [58]. Due to their significant 
vasodilatory effects attenuating the vasoconstriction and en-
dothelin-1 induced by immunosuppressant treatment, CCBs 
have been commonly used for the treatment of hypertension 
in these patients [58]. According to a review published in 
2011 on the management of hypertension in liver trans-
plant patients, dihydropyridine CCBs, such as nifedipine, 
isradipine, or amlodipine, are preferable due to their least 
interaction with the cytochrome P450 enzyme system and, 
therefore, carry the minimal risk of potential disruption of 
immunosuppressant levels. The authors also concluded that 
for the treatment of de novo hypertension after liver trans-
plantation, dihydropyridine CCBs should be used as first 
line drugs due to their potent vasodilatory effects [59].
Role of Kupffer cells (KC) and neutrophils
Liver inflammation can be induced by I/R but it is typically 
described as sterile inflammation compared to inflamma-
tion induced by invading pathogens. Similar to the response 
to invading microorganisms, the sterile inflammation in-
duced by I/R injury is characterized by the production of 
cytokines, chemokines, and other proinflammatory stimuli 
by mainly hepatic KCs and neutrophils [23, 60]. The KCs 
mainly mediate liver ischemic injury in the earlier stage of 
reperfusion (within 2 h) through synthesizing and librating 
ROS and the pro-inflammatory cytokines TNF-α and IL-
1to cause further activation of neutrophils and enhance the 
expression of the adhesion molecules intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) in liver SEC. This further promotes the adhesion, 
migration, and recruitment of neutrophils in the subsequent 
stage of reperfusion with release of potent oxidants, inflam-
matory cytokines, and proteases resulting in extensive collat-
eral damage to liver cells [61].
Neutrophil infiltration occurs as a result of inflammatory 
responses to necrotic cells and release of mediators and ROS 
by KCs and blocking of KCs activation by the use of gado-
linium chloride or methyl palmitate could reduce acute liver 
cell injury caused by I/R [62]. The sequestration of innate 
immune cells occurs primarily during reperfusion, which 
restores the delivery of oxygen and neutrophils to the tis-
sues. Although essential to support cellular metabolism, the 
flux of oxygen into the previously ischemic tissues fires the 
formation of ROS by enzymes such as XO and NADPH oxi-
dase by the invading neutrophils which will then direct their 
cytotoxic armory at parenchymal cells causing reperfusion 
injury that exacerbates cell damage and death caused by the 
previous ischemia [60].
Cytokines and downstream signaling
The complex relationship between cytokines and chemok-
ines in liver I/R injury is not fully understood. The activation 
of KCs leads to the release of wide array of pro-inflammato-
ry cytokines such as TNF-α, IL-1β, IL-6, platelet-activating 
factor (PAF) and other chemokines. Anti-inflammatory me-
diators are also released by activated KCs which consist of 
prostaglandins (PG), IL-4, IL-10 and IL-13 [63]. Serum level 
of TNF-α was found to rise within 30 min of reperfusion 
and persists for up to 8 h [64]. The major effect of TNF-α 
is to induce liver cell injury through neutrophil activation, 
ROS production, and mitochondrial toxicity [65]. TNF-α 
triggers expression of nuclear factor kappa beta (NFκB) and 
IL-1 which in turn upregulates the production of TNF-α in a 
positive feedback loop. Both TNF-α and IL-1β also increase 
expression of adhesion molecules in hepatic SEC. The role of 
these cytokines in hepatic I/R injury is further confirmed by 
experiments which show that their suppression by monoclo-
nal antibodies and receptor antagonists attenuates liver I/R 
injury [66].
Interferon (IFN)-β is a cytokine which is implicated 
throughout the reperfusion stage in liver I/R injury as shown 
from studies performed on knockout mice. The damaging 
effects of IFN-β are mediated by binding to IFN receptor 
subtype 1. Animal models deficient of this receptor showed 
modest hepatic injury after I/R [67]. Studies on animal 
knockout models have also confirmed the release of IFN-γ 
by the natural killer T cells (NKT) during the early period of 
reperfusion and its contribution to liver cell damage [68]. Ac-
tivation of toll-like receptor 4 (TLR4) on the surface of NKT 
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cells during liver I/R stimulates the release of both IFN-β and 
IFN-γ. The adverse effect of PAF in liver I/R injury was also 
demonstrated in rats pretreated with a specific PAF receptor 
antagonist. These rats exhibited suppression of the increased 
TNF-α and neutrophil attracting chemokines [69].
Not all inflammatory cytokines appear to be injurious 
in hepatic I/R injury. In agreement with this fact, Camargo 
and co-workers have early shown that IL-6 appears to play 
a protective role as evidenced by the finding of that I/R in-
jury in livers of IL-6 knockout mice was more severe than 
in wild type mice. Administration of recombinant IL-6 to 
the knockout mice before ischemia restored the mild type 
injury patterns seen in wild type mice [70]. There is some 
evidence that IL-4, IL-10 and IL-13, all of which are anti-in-
flammatory cytokines, may also play a protective role in I/R 
injury. An early study conducted on mice showed that IL-10 
suppressed expression of TNF-α, NF-κB activation, and sig-
nificantly reduced liver neutrophil recruitment, edema and 
cell injury following partial hepatic I/R injury [71]. A recent 
study performed with cerebral ischemia in IL-4 knockout 
mice which showed that IL-4 partially protects against isch-
emic brain injury in mice [72]. Chemokines, like cytokines, 
are a family of locally produced factors, but chemokines are 
smaller molecules, which act locally at site of inflammation 
to guide leukocyte chemotaxis. The chemokine, known as 
CXCL-10, was shown to contribute to liver I/R injury 1h 
after reperfusion onwards in association with activation of 
KCs and neutrophils and increased TNF-α and IL-1 release 
[73]. In agreement with this finding, a study conducted in 
2009 has shown that activation of chemokine receptor type 
2 contributes to liver injury during I/R and increase neutro-
phil recruitment [74].
Role of NF-κB
NF-κB is a pleiotropic transcription factor which is present 
in almost all cell types and is present as a homo- or heterod-
imeric complex formed by the Rel-like domain-containing 
proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL 
and NFKB2/p52 and the heterodimeric p65-p50 complex 
appears to be most abundant one. The dimers bind at kap-
pa-B sites in the DNA of their target genes and the individual 
dimers have distinct preferences for different kappa-B sites 
that they can bind with variable affinity and specificity. Dif-
ferent dimer combinations act as transcriptional activators 
or repressors. NF-κB is controlled by various mechanisms 
of post-translational modification and subcellular compart-
mentalization as well as by interactions with other cofactors 
or corepressors [75]. 
NF-κB is best known for its function in the expression 
of immunoregulatory genes relevant in many biological 
processes such as inflammation, immune response, cell 
differentiation and growth, tumorigenesis and apoptosis. 
In particular, NF-κB plays a pivotal role in regulating the 
transcription of cytokines TNF-α, adhesion molecules, and 
other cytokines and chemokines. In resting cells, NF-κB is 
retained in an inactive state in the cytoplasm by direct bind-
ing to an inhibitor of NF-κB (I-κB) protein. In response to 
inflammatory stimuli, including ROS and TNF-α, I-κB pro-
teins are phosphorylated and degraded. Degradation of I-κB 
proteins unmasks the nuclear localization sequence of NF-
κB subunits, allowing NF-κB to translocate to the nucleus 
and bind specific promoter elements and induces gene tran-
scription [76].
During the reperfusion period, activated neutrophils in-
filtrate tissues and adhere to hepatic SEC through adhesion 
molecules, resulting in localized release of proteases, ROS 
and various cytokines and inflammatory mediators that 
activate NF-κB and contribute to tissue injury. The activa-
tion of NF-κB in rats subjected to warm liver I/R injury was 
shown to occur within 1–2 h after the initiation of reperfu-
sion and decreases after 4 h. NF-κB furthermore upregulates 
the expression of cytokines, like TNF-α, and of ICAM-1 and 
VCAM-1, enhancing the recruitment of neutrophils. TNF-α 
and many other cytokines in addition of being triggered by 
NF-κB but can also directly upregulate it, thus establishing 
a positive feedback loop that can amplify the inflammato-
ry response and extend the duration of inflammation. The 
damage in I/R injury therefore spreads throughout the entire 
tissue [77]. Reported results suggest that decreased NF-κB 
activation and subsequent reduction in TNF-α level are im-
portant in the protective mechanism of hepatic I/R injury. 
Inhibition of XO derived ROS generation in activated neu-
trophils by allopurinol was also shown to markedly diminish 
NF-κB activation and attenuate hepatic [78] and renal [79] 
I/R injury in rat models.
Adhesion molecules
The adhesion of neutrophils to hepatic parenchymal cells 
and SEC, and migration into liver tissue require sequential 
steps in which many adhesion molecules are involved. The 
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selectin category of adhesion molecules (P, E and L-selec-
tin) are expressed by SEC early in reperfusion to mediate 
adhesion of platelets and neutrophils. Studies have shown 
that P-selectin expression is raised 20 to 30 min after reper-
fusion [80]. Other researchers have suggested that E-selectin 
expression, and not P-selectin, is required for I/R injury to 
occur [81]. This is followed by stronger adhesion of leuko-
cytes on SEC by upregulation of other adhesion molecules 
such as VCAM-1 and ICAM-1. By doing so, they migrate 
across the endothelium into the liver parenchyma enhancing 
ROS production and degranulation of cytoplasmic vesicles 
containing enzymes capable to degrade extracellular matrix 
and hepatocytes.
Role of Renin-Angiotensin System (RAS) 
The implication of the renin–angiotensin system (RAS) in 
cardiac and renal pathology has been subject of substantial 
body of research, as it may synchronize fibrosis and tissue 
repair, and is consequently a goal for treatment with RAS 
blockers. In addition to the systemic RAS, many tissues and 
organs can express local functional RAS components that 
are regulated by incentives within the same organ. Recent 
research has pointed at the presence of local RAS in the liver, 
and its role in the pathogenesis of liver disease and fibro-
genesis [82]. Both local and systemic RAS appear to play bi-
modal role in tissue remodeling and scarring, especially after 
injury [83]. 
The ‘classical’ RAS includes principally angiotensin II 
(Ang-II), angiotensin-converting enzyme (ACE) and the 
Ang-II type 1 (AT1) receptor, and is responsible for, not 
only sodium homoeostasis and vasoconstriction by acting 
on vascular smooth muscle cells, but also has a role in in-
flammation, cytokine production, cell proliferation, and 
tissue repair. It is also involved in the pathogenesis of the 
metabolic syndrome through its effects on fat metabolism 
and insulin sensitivity [84]. Other components of the RAS 
that may mediate inflammation and fibrosis include the pro-
renin receptor, which is likely to have intracellular functions 
beyond its role as a receptor for renin and prorenin. Another 
‘alternative’ RAS has been identified in both human and ro-
dents. It consists of a structural homologue of ACE, named 
ACE2, which shares more than 40% structural similarity 
with ACE [85]. ACE2 is able to cleave both Ang-I to Ang-
(1–9) and Ang-II to Ang-(1–7) respectively. Many effects 
mediated by Ang-(1–7) appear to oppose those of Ang-II 
and the AT1 receptors, and include vasodilation, improve-
ment of endothelial function, inhibition of cell proliferation, 
and antithrombotic effects [86]. There is increasing evidence 
that Ang-(1–7), beside its effect on its specific Mas receptor; 
it may also mediate part of its effects via the AT2 receptors. 
Several researches have studied the expression of RAS 
components in the liver both in animal models of hepatic 
fibrosis and in human tissue samples. In an elegant binding 
study, Bataller and co-workers demonstrated that hepatic 
stellate cells (HSC) express the AT1 receptor and that Ang-II 
exerted a marked concentration-dependent increase in in-
tracellular calcium levels, cell contraction and proliferation. 
Paizis and co-workers demonstrated that gene expression of 
both ACE and AT1 receptor were upregulated in the liver 
by bile duct ligation, and were specifically marked in areas 
of active hepatic fibrogenesis [87]. In addition, Ang-II was 
shown to stimulate gene expression of transforming growth 
factor-beta (TGF-β) and fibronectin by activating AT1 re-
ceptors in KC. In human samples of advanced fibrotic liv-
er, the expression of AT1 receptors was downregulated in 
hepatocytes, while it was upregulated in HSC, vascular en-
dothelium and bile duct epithelium [88]. In addition to the 
above-mentioned effects of RAS in the development of liver 
fibrosis, results of recent research have shown that this sys-
tem also plays a proinflammatory role in tissue, however, the 
mechanisms by which the RAS may play a role in mediat-
ing hepatic inflammation remains largely not well-under-
stood. Several researches have shown that Ang-II stimulates 
expression of proinflammatory cytokines and chemokines, 
adhesion molecules such as ICAM-1, and activates proin-
flammatory transcription factors such as NF-κB [89]. In 
the liver, both KC and SEC have been shown to respond to 
Ang-II to produce proinflammatory and profibrotic cyto-
kines, chemokines and ROS. Harrison and co-workers have 
demonstrated that Ang-II increases superoxide production 
via direct activation of NADPH oxidase [90].
Although a substantial body of data in the literature has 
documented the role of RAS in liver diseases, inflammation, 
and fibrosis, little is known about the role of RAS and/or its 
blockers in the pathogenesis/protection of hepatic I/R injury. 
The very few studies available in this topic yielded inconsis-
tent conclusions. In rodent models of hepatic I/R injury, Guo 
and co-workers have shown that blocking of the systemic of 
RAS by captopril and lisinopril could effectively protect the 
liver during IR. The authors concluded that this effect was 
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possibly through inhibition of TNF-α and ICAM-1 [91]. In 
another study, lisinopril could effectively attenuate liver I/R 
injury in rat model. The author concluded that this effect 
was possibly by improving nitric oxide availability and re-
ducing oxidative stress [92].
Treatment options to ameliorate I/R injury in 
liver transplantation
Pharmacological treatment is believed to be effective to re-
duce I/R injury in liver transplantation based on data avail-
able today from experimental research. Most of the studied 
agents have short-term survival benefits identified in exper-
imental researches; therefore, the identified agents should be 
further evaluated in human clinical trials. A recent metanal-
ysis study has reviewed the available pharmacological agents 
to reduce hepatic I/R injury in rat liver transplantation [93]; 
however, none of these pharmacological agents against I/R 
injury have become part of the clinical routine.
Antioxidants
Because of the strong evidence for the importance of ROS in 
hepatic I/R injury, a number of different intervention strate-
gies have been successfully used in multiple models of warm 
and cold I/R injury.
Xanthine oxidase (XO)
This hypothesis was mainly based on XO being invoked as 
a critical source of ROS during I/R injury, and the protec-
tive effect of the XO inhibitor allopurinol [79]. Unfortunate-
ly, there are multiple reasons for the limited importance of 
this approach under clinically relevant conditions. First, the 
enzyme XO exists as xanthine dehydrogenase and the con-
version to the ROS-generating oxidase requires long time of 
ischemia. In addition, the ROS formation depends on the 
substrates xanthine and hypoxanthine which are relatively 
fast metabolized and flushed out together with other metab-
olites from the liver during reperfusion.
Glutathione (GSH)
The tripeptide glutathione (GSH), present in high concen-
trations in hepatocytes, is a highly effective antioxidant by 
serving as an electron donor. Intravenous infusion of GSH 
has been shown to protect against reperfusion injury follow-
ing rat liver transplantation [94]. On the other hand, treat-
ment with the cysteine derivative N-acetylcysteine (NAC) 
can increase intracellular GSH levels and strengthen the 
defense arsenal when given before liver I/R. Furthermore, 
clinical trials have reached phase IV for the use of NAC as 
a protective agent against both warm and cold ischemia 
during liver surgeries [95]. Gene transfer of glutathione syn-
thesis components glutamine cysteine ligase catalytic sub-
unit, glutamine cysteine regulatory subunit, and glutathione 
synthase are attractive options to protect against I/R injury 
by increasing intracellular GSH levels [96].
Superoxide dismutase (SOD)
Administration of exogenous catalase or superoxide dis-
mutase (SOD) was among earliest interventions as a pre-
treatment before ischemic injury. Consequentially, induction 
or maintenance of SOD levels has become another common 
explanation for mechanism of protection by numerous sub-
stances [97]. However, even intravenous administration of 
high doses resulted in only partial protection, largely due to 
poor bioavailability of the enzyme. Thus, potential antioxi-
dant therapies using modified variants of SODs, or catalase, 
may be alternative option. 
α-Tocopherol
α-tocopherol is a vitamin E analogue that is favorably ab-
sorbed in humans. In an early study, oral pretreatment with 
α-tocopherol attenuated I/R injury and lipid peroxidation 
and increased synthesis of ATP when compared to control 
mice. The effect on cellular ATP levels suggests that this 
treatment improved mitochondrial function. However, in a 
double-blind randomized placebo controlled trial, treatment 
with a full racemic mixture of α-tocopherol showed no re-
duction in clinical outcome [98]. A latest mixture composed 
of vitamin E, taurine, and GSH showed a reduction in hepat-
ic I/R injury in rats [99]. This suggests that a combination of 
more than one antioxidant may be more effective than em-
ploying a single one.
Ischemic preconditioning
Ischemic preconditioning is probably the most common 
method investigated for reducing I/R injury. It relies on ex-
posing the liver to a short period of ischemia then reper-
fusion before the real period of hepatic ischemia. Ischemic 
preconditioning has been shown to reduce inflammatory 
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response as well as attenuate oxidant stress [100]. The mech-
anisms underlying the preconditioning effect involve activa-
tion of the prosurvival p38/MAPK signaling pathway [101], 
induction of antioxidant stress response genes such as heme 
oxygenase-1, and increased hepatocyte proliferation in re-
sponse to ischemic challenge [102]. There is evidence that 
ischemic preconditioning shows beneficial promise in the 
clinical settings. Ischemic postconditioning has also been 
shown to be protective against I/R injury and has similar 
mechanisms as to preconditioning, such as activation of the 
prosurvival PI3K/Akt signaling pathway and induction of 
antioxidant enzymes such as SOD and the vasodilator nitric 
oxide [103]. 
MPT pore prevention
As discussed in section 3.2., opening of MPT pore in the in-
ner mitochondrial membrane is a critical event in mitochon-
drial toxicity and progression of cell death in response to I/R 
injury. A number of treatments have been tried to decrease 
MPT pore during I/R principally by preventing extracellular 
ROS generation, including administration of melatonin and 
edaravone [32-33]. Edaravone is an intravenous drug that 
has been used to help people recover from stroke in Japan 
since 2001.  In May 2017, edaravone was FDA approved to 
treat patients with amyotrophic lateral sclerosis (ALS) in the 
United States [104]. Although originally designed for use 
in ischemic stroke, the drug inhibited MPT pore formation 
and exerted good preservation of mitochondrial respiration 
potential and a reduction in mitochondrial swelling when 
given before I/R of liver [33] and brain [105], most probably 
owing to its strong antioxidant properties.
Targeting inflammatory cytokines/chemok-
ines
The protective roles of IL-4, IL-10, IL-12, IL-13 and IL-18, all 
of which are anti-inflammatory cytokines, have been investi-
gated in animal models of liver I/R injury. A study performed 
on mice showed that injection of recombinant murine IL-
10 after partial hepatic I/R injury suppressed expression of 
TNF-α, NF-κB and significantly reduced neutrophil recruit-
ment, inflammation and hepatocellular injury. Viral gene 
transfer of IL-10 and injection of hypertonic saline solu-
tion which also increases IL-10 levels also reduced hepatic 
I/R injury. Xiong and co-workers have recently shown that 
IL-4 partially protects against ischemic brain injury in IL-4 
knockout mice [72]. 
A murine model was used to explore the role of IL-12 fol-
lowing hepatic I/R injury. Hepatic ischemia for 90 min fol-
lowed by reperfusion for 4 h resulted in hepatocyte expres-
sion of IL-12. Hepatocellular injury, neutrophil recruitment, 
increased TNF- α and serum ALT were markedly reduced 
after administration of neutralizing antibody to IL-12 [106]. 
The histamine agonist, dimaprit, also exerted protective ef-
fects in liver I/R injury by decreasing IL-12 level. The role 
of IL-13, an antiinflammatory cytokine, was also studied in 
murine model of hepatic I/R injury. Endogenous IL-13 de-
creased hepatocellular injury, neutrophil recruitment, and 
TNF-α level [107]. To the opposite of PAF, prostaglandin-E1 
(PGE-1) was found to have protective effect in liver I/R inju-
ry. Infusion of PGE-1 was demonstrated to markedly reduce 
plasma alanine aminotransferase (ALT), TNF-α, ICAM-1, 
VCAM-1, P- and E-selectin in canine model of hepatic I/R 
injury [108]. A similar, but earlier, study conducted on rats 
confirmed the cytoprotective effect of PGE-1 and indicat-
ed that protection against I/R injury by PGE-1 occurs most 
probably through down-regulation of ICAM-1 [109]. 
Interventions inhibiting NF-κB
The NF-κB is a key regulator of inflammatory cytokines in 
I/R injury. As mentioned earlier it is kept quiescent in rest-
ing cells by complexing with its specific inhibitory protein 
I-κB. This I-κB when become phosphorylated, it degrades 
away unmasking the binding sequence of NF-κB to be able 
to bind its specific site on DNA and affect gene transcrip-
tion. Some therapeutic trials relied on prevention of NF-κB 
activation through inhibition of I-κB degradation in the set-
ting of experimental myocardial infarction [110]. However, 
this approach warrants further investigation in the setting 
of transplantation. Another way to inhibit I-κB breakdown 
would be the inhibition of proteasomes responsible for its 
degradation and thus, termination of function, of specifi-
cally marked proteins. In hepatic, renal, as well as cerebral 
ischemia the respective injury could be prevented by admin-
istration of proteasome inhibitor lactacystin or its derivative 
PS519. Experimental protocols analyzing the effects of gene 
therapy such as interference with NF-κB translocation have 
been also introduced. However, all these approaches have 
not been yet translated into larger clinical trials.
Abdel-Ghany et al. 2018 Hepatic ischemia-reperfusion injury: A review
© 2018, The Authors Adv Med Med Res, 2018;1(1):2-18
ISSN 2535-2210
14
Interventions inhibiting adhesion molecules
Adhesion molecules, such as ICAM-1 and VCAM-1, are 
necessary for adhesion of neutrophils to liver cells and their 
infiltration into liver tissue. Experimental evidence suggests 
that a reduced expression of adhesion molecules ameliorates 
renal and hepatic I/R injury. In phase I and II study, an an-
ti-ICAM-1 antisense-oligonucleotide was analyzed in order 
to prevent acute graft rejection. Unfortunately, the oligonu-
cleotide did not further reduce the rate of acute rejections or 
improved graft survival as compared to a conventional im-
munosuppressive protocol [111]. 
TBC-1269 is an investigational inhibitor of more than 
one selectin member (i.e. multiselectin inhibitor) that re-
duced serum levels of the pro-inflammatory TNF-α and 
augmented levels of the anti-inflammatory cytokine IL-10 
after liver I/R [112]. The multiselectin inhibitor OC-229 also 
provided significant protection to the ischemic liver includ-
ing reduction of NF-κB activation [113]. However, while 
anti-adhesion molecule targeted therapies show some prom-
ise in experimental organ transplantation, more data is still 
needed before the clinical significance of this therapeutic in-
tervention can be examined.
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